SCAF4 Antibody

What is SCAF4 and what is its primary function in cellular processes?

SCAF4 functions as an mRNA anti-terminator protein that prevents premature transcription termination. It binds to the hyperphosphorylated C-terminal repeat domain (CTD) of RNA polymerase II that is phosphorylated on both Ser2 and Ser5. This binding suppresses the use of early, alternative polyadenylation (polyA) sites, ensuring proper mRNA processing .

SCAF4 works in conjunction with its paralog SCAF8, with which it shares significant sequence homology (38% identity and 50% similarity). Both proteins contain a CTD-interaction domain (CID) characteristic of termination factors. While they have redundant anti-termination functions, they also possess distinct roles—SCAF8 acts as an RNA polymerase II elongation factor, whereas SCAF4 is required for correct termination at canonical, distal transcription termination sites when SCAF8 is present .

What are the key structural properties of SCAF4 protein that researchers should consider when selecting antibodies?

SCAF4 in humans has the following key characteristics:

• Canonical protein length: 1147 amino acid residues

• Molecular weight: 125.9 kDa

• Subcellular localization: Nucleus

• Number of reported isoforms: Up to 3 different isoforms

• Expression pattern: Widely expressed across many tissue types

The protein contains a CTD-interaction domain (CID) that is critical for its function in binding to RNA polymerase II. When selecting antibodies, researchers should consider which domain or epitope they wish to target based on their experimental goals. For instance, antibodies targeting the CID region would be valuable for studies examining SCAF4's interaction with RNA polymerase II, while antibodies against other regions might be more suitable for general detection purposes .

How do SCAF4 variants contribute to neurodevelopmental disorders?

Recent research has identified SCAF4 variants in individuals with neurodevelopmental disorders. The molecular spectrum includes:

• 25 truncating variants

• 8 splice-site variants

• 5 missense variants

Clinically, individuals with SCAF4 variants frequently exhibit:

• Mild developmental delay with speech impairment

• Seizures

• Skeletal abnormalities (clubfoot, scoliosis, hip dysplasia)

• Cognitive abilities ranging from normal IQ to severe intellectual disability, with most showing borderline to mild intellectual disability

Researchers investigating SCAF4's role in neurodevelopment should consider using antibodies that can differentiate between wild-type and mutant protein forms, particularly for missense variants in the CTD-interacting domain that may destabilize the domain structure .

What are the optimal conditions for Western Blot detection of SCAF4?

Based on validated protocols for SCAF4 antibodies, researchers should consider the following parameters for Western Blot applications:

For optimal results, tissue or cell lysate preparation should include phosphatase inhibitors, as SCAF4 is known to interact with phosphorylated proteins .

How should researchers validate SCAF4 antibody specificity for experimental applications?

Proper validation of SCAF4 antibodies is crucial for experimental reliability. A comprehensive validation approach should include:

• Positive and negative controls:

  • Use cell lines with known SCAF4 expression as positive controls

  • Include SCAF4 knockout cell lines as negative controls when available (SCAF4 single KO cells have been generated and characterized)

• Blocking peptide experiments:

  • Pre-incubate antibody with the immunizing peptide before application

  • Observe disappearance of specific signals in Western blot or immunostaining

• siRNA or CRISPR knockout validation:

  • Compare antibody signal between wild-type cells and those with SCAF4 knockdown/knockout

  • Ensure signal reduction corresponds to reduction in SCAF4 expression

• Cross-reactivity assessment:

  • Test against SCAF8 protein (38% identity) to ensure specificity

  • Particularly important when studying both proteins simultaneously

• Multiple antibody comparison:

  • Use antibodies targeting different epitopes of SCAF4

  • Consistent results across different antibodies support specificity

What considerations are important for immunohistochemical detection of SCAF4?

For optimal immunohistochemical (IHC) detection of SCAF4, researchers should consider:

Given SCAF4's nuclear localization, nuclear staining patterns should be expected. Cytoplasmic staining may indicate non-specific binding or altered localization in pathological conditions .

How can researchers use SCAF4 antibodies to study its interaction with RNA polymerase II?

To investigate SCAF4's interaction with RNA polymerase II (RNAPII), researchers can employ these methodological approaches:

• Co-immunoprecipitation (Co-IP):

  • Use anti-SCAF4 antibodies to pull down protein complexes

  • Probe for RNAPII in the precipitated material with antibodies specific to phosphorylated CTD (both Ser2 and Ser5 phosphorylation)

  • Include controls with non-specific IgG and SCAF4 knockout cells

• Proximity Ligation Assay (PLA):

  • Utilize antibodies against SCAF4 and RNAPII CTD

  • PLA signals will only appear when proteins are in close proximity (<40 nm)

  • Can distinguish between interactions with differently phosphorylated forms of RNAPII

• Chromatin Immunoprecipitation (ChIP):

  • Perform sequential ChIP (first with RNAPII antibodies, then with SCAF4 antibodies)

  • Analyze enrichment at genes known to be regulated by SCAF4/SCAF8

  • Compare enrichment patterns at canonical termination sites versus alternative polyadenylation sites

What methodologies are recommended for investigating SCAF4-RNA interactions using antibody-based techniques?

SCAF4 binds to nascent RNA transcripts, and this interaction can be studied using:

• RNA Immunoprecipitation (RIP):

  • Use validated SCAF4 antibodies to precipitate protein-RNA complexes

  • Extract and analyze associated RNAs by RT-qPCR or sequencing

  • Include appropriate RNase controls

• Photoactivatable Ribonucleoside-Enhanced Crosslinking and Immunoprecipitation (PAR-CLIP):

  • Incorporate 4SU into nascent RNA

  • UV crosslink at 365 nm wavelength

  • Immunoprecipitate SCAF4 and isolate associated RNA

  • Sequence and analyze T→C transitions indicative of crosslinking sites

  • This approach has successfully identified SCAF4 binding sites with high confidence

• Individual-nucleotide resolution Crosslinking and Immunoprecipitation (iCLIP):

  • Compare binding patterns at genes with alternative polyadenylation sites

  • Analyze motif enrichment (SCAF4 binding sites show several short, low-complexity, C/G-rich RNA-binding motifs, including CG[G/A], [C/G]CAG[C/G], and C[U/A]CC)

The research indicates that SCAF4 binding peaks 50–200 nt upstream of proximal polyA sites, suggesting it recognizes elements within nascent RNA as it emerges from the RNAPII elongation complex .

How can researchers use antibodies to study the functional redundancy and distinct roles of SCAF4 and SCAF8?

To investigate the redundant and distinct functions of SCAF4 and SCAF8, consider these methodological approaches:

• Differential expression analysis in knockout models:

  • Compare protein expression patterns using specific antibodies in:

    • Wild-type cells

    • SCAF4 single knockout cells

    • SCAF8 single knockout cells

    • SCAF4/SCAF8 double knockout cells with inducible rescue constructs

  • Analyze changes in target gene expression and protein isoforms

• ChIP-seq comparative analysis:

  • Perform ChIP-seq with both SCAF4 and SCAF8 antibodies

  • Compare genome-wide binding patterns and identify:

    • Shared binding sites (redundant functions)

    • Unique binding sites (distinct functions)

  • Correlate binding sites with alternative polyadenylation patterns

• Rescue experiments with domain swaps:

  • Generate constructs where specific domains are swapped between SCAF4 and SCAF8

  • Use antibodies to confirm expression levels

  • Assess functional rescue in knockout backgrounds

Research indicates that while SCAF4 and SCAF8 share redundant anti-terminator functions, SCAF4 specifically regulates termination at canonical distal sites when SCAF8 is present, while SCAF8 functions as an elongation factor .

What are common challenges when detecting SCAF4 in different experimental systems?

Researchers may encounter several challenges when working with SCAF4 antibodies:

When encountering these issues, it's advisable to consult the literature for specific experimental conditions that have worked for SCAF4 detection in similar systems .

How should researchers interpret SCAF4 antibody data in the context of neurodevelopmental disorders?

When using SCAF4 antibodies to study neurodevelopmental disorders:

• Expression level analysis:

  • Compare SCAF4 expression between affected and control tissues

  • Consider that changes may be subtle and cell-type specific

  • Quantify expression using image analysis software for immunohistochemistry or densitometry for Western blots

• Localization patterns:

  • Evaluate nuclear versus cytoplasmic distribution

  • Assess co-localization with RNAPII and other transcription factors

  • Compare patterns between normal and pathological samples

• Isoform detection:

  • Different variants may affect specific isoforms

  • Use antibodies capable of distinguishing isoforms when possible

  • Correlate isoform expression with specific phenotypes

• Variant-specific considerations:

  • For truncating variants: Antibodies targeting N-terminal epitopes may still detect truncated proteins

  • For missense variants: Expression levels may be normal but function impaired

  • For splice-site variants: Multiple aberrant protein products may be detected

Research has shown that SCAF4 variants are associated with developmental delay, speech impairment, seizures, and skeletal abnormalities, with cognitive effects ranging from normal to severe intellectual disability .

What strategies can optimize detection of SCAF4 in co-immunoprecipitation experiments?

For successful co-immunoprecipitation of SCAF4 with its interaction partners:

• Crosslinking optimization:

  • For transient interactions, consider mild formaldehyde crosslinking (0.1-0.3%)

  • Optimize crosslinking time to preserve interactions without masking epitopes

• Lysis conditions:

  • Use gentle lysis buffers containing 150-300 mM NaCl

  • Include phosphatase inhibitors to preserve CTD phosphorylation status

  • Consider including RNase inhibitors if RNA-mediated interactions are relevant

• Antibody selection:

  • Choose antibodies validated for immunoprecipitation

  • Avoid antibodies targeting interaction interfaces

  • Consider using tagged versions of SCAF4 and corresponding tag antibodies

• Washing stringency:

  • Balance between maintaining specific interactions and reducing background

  • Consider a gradient of wash buffers with decreasing salt concentrations

• Detection methods:

  • For known interactions: Western blot with specific antibodies

  • For novel interactions: Mass spectrometry analysis

  • Confirm interactions using reciprocal immunoprecipitation

How might SCAF4 antibodies be utilized in emerging single-cell transcriptomics research?

As single-cell techniques continue to advance, SCAF4 antibodies could contribute to understanding transcriptional regulation at the single-cell level:

• Single-cell protein and RNA co-detection:

  • Use SCAF4 antibodies in CITE-seq or REAP-seq protocols

  • Correlate SCAF4 protein levels with transcriptome-wide alternative polyadenylation patterns

  • Identify cell populations with distinct SCAF4 activity

• Spatial transcriptomics applications:

  • Employ SCAF4 antibodies in multiplexed immunofluorescence imaging

  • Correlate spatial SCAF4 expression with local transcriptional profiles

  • Identify tissue regions with differential mRNA processing patterns

• In situ protein-RNA interaction detection:

  • Adapt proximity ligation assays to detect SCAF4-RNA interactions in tissue sections

  • Map the spatial distribution of SCAF4 activity across developing brain regions

These approaches could provide insights into how SCAF4-mediated transcriptional regulation contributes to cellular heterogeneity in normal development and disease states .

What are the key methodological considerations for studying SCAF4 in patient-derived samples?

When investigating SCAF4 in clinical specimens:

• Sample preparation optimization:

  • For fresh tissues: Rapid fixation to preserve nuclear architecture

  • For FFPE samples: Extended antigen retrieval may be necessary

  • For blood/cell samples: Consider nuclear extraction to enrich SCAF4

• Patient stratification:

  • Group samples by variant type (truncating, missense, splice-site)

  • Consider genotype-phenotype correlations

  • Include age and sex-matched controls

• Multiplex approaches:

  • Combine SCAF4 detection with markers of neuronal maturation

  • Co-stain for SCAF8 to assess compensatory mechanisms

  • Include markers for alternative polyadenylation to assess functional impact

• Quantitative assessment:

  • Develop scoring systems for SCAF4 expression and localization

  • Use digital pathology tools for unbiased quantification

  • Correlate findings with clinical severity metrics

Recent research has expanded the known clinical spectrum of SCAF4-associated disorders, making careful phenotypic characterization alongside molecular analysis essential for advancing understanding of this condition .